4Chudleigh R A, Ollerton R L, Dunseath G, et al. Use of cystatin C - based estimations of glomerular filtration rate in patients with type 2 diabetes. Diabetologia, 2009,52(7) : 1274.
5Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a pre- dictor of outcome in a broad spectrum of patients with heart failure [ J 1. Circulation, 2006,113 ( 5 ) :671-678.
6Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008[J]. Eur Heart J, 2008,29(19) :2388-2442.
7Shlipak MG, Samak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons[J]. N Engl J Med, 2005,352(20) :2049-2060.
8Shlipak MG, Katz R, Samak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons withoutchronic kidney disease[ J]. Ann Intern Med, 2006,145 (4) :237- 246.
9Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concen- tration as a risk factor for heart failure in older adults [ J ]. Ann In- tern Med, 2005,142 ( 7 ) :497-505.
10Shlipak MG, Katz R, Fried LF, et al. Cystatin C and mortality in elderly persons with heart failure[ J]. J Am Coll Cardiol, 2005,45 (2) :268-271.
4Yang B,Mo Z,Wu C,et al.A genome-wide association study immutifies common variants influencing serum uric caid concentrations in s chinese population[J].BMC Med Genomics,2014,7:10.
5Tanaka K,Hara S,Hattori M,et al.Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2diabetes[J].Jdiabetes Investing,2015,6(1):98-104.
